Using 18F-FDG-PET/CT Metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers.
18F-FDG-PET/CT
RAI-refractory
prognostic factors
thyroid cancer
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
30 Sep 2022
30 Sep 2022
Historique:
received:
26
08
2022
revised:
21
09
2022
accepted:
27
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Radio-iodine refractory (RAI-R) differentiated thyroid cancer (DTC) is a rare disease with a poor prognosis and limited therapeutic resources. Therefore, identifying prognostic factors is essential in order to select patients who could benefit from an early start of treatment. The aim of this study is to identify positron emission tomography with 18F-fluorodeoxyglucose with integrated computed tomography (18F-FDG-PET/CT) parameters to predict overall survival (OS) in patients with RAI-R DTC. In this single-center retrospective study, we analyze the 18F-FDG-PET/CT parameters of 34 patients with RAI-R DTC between April 2007 and December 2019. The parameters collected are MTV, SUVmax and progression for each site of metastasis (neck, mediastinum, lungs, liver, bone) and total sites. ROC curves, Kaplan-Meier survival analysis curves, univariate and multivariate Cox analyses determine prognostic factors for 1-year and 5-year OS. The parameters for mediastinum, liver and total sites are significantly associated with worse 1-year and 5-year OS by both ROC curve analysis and Kaplan-Meier survival analysis. Univariate Cox analysis confirms significance of mediastinum SUVmax (HR 1.08; 95% CI [1.02-1.15];
Identifiants
pubmed: 36292070
pii: diagnostics12102381
doi: 10.3390/diagnostics12102381
pmc: PMC9600595
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Endocr Relat Cancer. 2011 Aug 30;18(5):R165-74
pubmed: 21632805
Clin Nucl Med. 2015 Jun;40(6):469-75
pubmed: 25899591
Lancet Oncol. 2007 Feb;8(2):148-56
pubmed: 17267329
Thyroid. 1996 Dec;6(6):607-11
pubmed: 9001196
N Engl J Med. 2016 Sep 15;375(11):1054-67
pubmed: 27626519
Am J Med. 1994 Nov;97(5):418-28
pubmed: 7977430
J Clin Endocrinol Metab. 2009 Apr;94(4):1310-6
pubmed: 19158200
Thyroid. 2017 Sep;27(9):1135-1141
pubmed: 28665259
PLoS One. 2019 Jun 25;14(6):e0218416
pubmed: 31237886
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Endocr Relat Cancer. 2011 Jan 13;18(1):159-69
pubmed: 21118976
Thyroid. 2017 Jun;27(6):751-756
pubmed: 28463585
Cancer. 2008 Jul 1;113(1):48-56
pubmed: 18484584
Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):295-305
pubmed: 28911726
Lancet Diabetes Endocrinol. 2014 May;2(5):356-8
pubmed: 24795243
J Clin Endocrinol Metab. 1995 Jul;80(7):2041-5
pubmed: 7608252
BMC Cancer. 2019 Dec 12;19(1):1209
pubmed: 31830943
J Clin Endocrinol Metab. 2006 Feb;91(2):498-505
pubmed: 16303836
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):638-646
pubmed: 27796544
F1000Prime Rep. 2015 Feb 03;7:22
pubmed: 25750740
Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8
pubmed: 8256208
Eur J Cancer (1965). 1979 Aug;15(8):1033-41
pubmed: 510341
Crit Rev Oncol Hematol. 2014 Jun;90(3):233-52
pubmed: 24405857
Endocr Relat Cancer. 2018 Apr;25(4):R209-R223
pubmed: 29371330
Eur J Endocrinol. 2012 Nov;167(5):643-50
pubmed: 22918300
Endocr Pract. 2017 Oct;23(10):1193-1200
pubmed: 28704099
Diagnostics (Basel). 2022 Feb 16;12(2):
pubmed: 35204596
Oncologist. 2016 Jan;21(1):50-8
pubmed: 26675742
Eur J Cancer. 2006 Oct;42(15):2598-608
pubmed: 16979888
Eur Thyroid J. 2019 Oct;8(5):227-245
pubmed: 31768334
J Clin Oncol. 2017 Oct 10;35(29):3315-3321
pubmed: 28817373
Endocrine. 2019 Nov;66(2):254-265
pubmed: 31317522
J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9
pubmed: 16684830
Lancet. 2014 Jul 26;384(9940):319-28
pubmed: 24768112
J Clin Endocrinol Metab. 2000 Mar;85(3):1107-13
pubmed: 10720047
N Engl J Med. 2015 Feb 12;372(7):621-30
pubmed: 25671254
Clin Endocrinol (Oxf). 2005 Jul;63(1):87-93
pubmed: 15963067
J Clin Endocrinol Metab. 1999 Nov;84(11):4043-9
pubmed: 10566647
J Clin Oncol. 2008 Oct 10;26(29):4701-4
pubmed: 18541893
Ann Surg. 2007 Mar;245(3):366-78
pubmed: 17435543
Clin Nucl Med. 2018 Sep;43(9):641-647
pubmed: 30015659
Cancer Res. 1991 Feb 15;51(4):1234-41
pubmed: 1997164
N Engl J Med. 2008 Jul 3;359(1):31-42
pubmed: 18596272
Endocr Relat Cancer. 2015 Dec;22(6):R301-10
pubmed: 26307020
Ann Surg. 2010 Jan;251(1):114-9
pubmed: 19779325
Arch Endocrinol Metab. 2017 May-Jun;61(3):222-227
pubmed: 28699989
Thyroid. 2016 Mar;26(3):373-80
pubmed: 26914539
J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9
pubmed: 18682506
Thyroid. 2019 Apr;29(4):461-470
pubmed: 30900516
Cancer. 1988 Oct 1;62(7):1381-8
pubmed: 3416277
Surgery. 2004 Sep;136(3):609-16
pubmed: 15349109
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
J Clin Endocrinol Metab. 2006 Jan;91(1):313-9
pubmed: 16263822
Thyroid. 2011 Jul;21(7):707-16
pubmed: 21649472